Valneva Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth

Appointment of David Lawrence as Chief Financial Officer (CFO)Appointment of Wolfgang Bender, MD, PhD as Chief Medical Officer (CMO)

Valneva SE (“Valneva” or “the Company”), a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, is pleased to announce the expansion of its Management Board with two new appointments: David Lawrence as Chief Financial Officer (CFO) and Wolfgang Bender, MD, PhD as Chief Medical Officer (CMO). Mr. Lawrence’s and Dr. Bender´s appointments by the Company´s Supervisory Board will become effective on August 7thand September 1st respectively.

David Lawrence, a British national, brings over 25 years of experience in the pharmaceutical, biotech and vaccine industries, with a proven international track record in mid-sized to large companies and small biotech start-ups. His tested leadership experience as a CFO in the Lifesciences sector spans across finance and accounting, mergers and acquisitions, fund raising and investor relations. David served as CFO in a dual-listed (LSE and NASDAQ) vaccine biotech company (Acambis plc, acquired by sanofi in 2008) and was Vice President of Finance & Business Development for Chiron Vaccines, a division of Chiron Corporation which was acquired by Novartis in 2005. Prior to these roles, he held senior finance positions at GlaxoSmithKline including Vice President of Financial Management in Research and Development.

In addition, David also brings recent start-up CEO experience and Non-Executive Director / Board experience. Dr Wolfgang Bender, MD, PhD, a German national, is a global life sciences leader with over 30 years of extensive experience in scientific-medical affairs, R&D and general management of vaccines and pharmaceuticals. He brings a broad international profile with an exceptional academic background (MD, PhD, MPH, MHA, DTM&P). Wolfgang has special competencies in strategy, operational execution and change management, with a record of success working in leadership roles for leading global life sciences companies. He held a variety of senior and international positions in vaccine development and medical affairs, working for leading companies in the field, including Novartis Vaccines and Takeda Vaccines. Prior positions included country manager, corporate strategy and various clinical research roles at major pharmaceutical companies such as Pfizer and the Hoechst Group. In the last twelve months, Dr. Bender has provided consulting services to Valneva.

Valneva’s Suervisory Board has also confirmed the appointment of the Company’s General Counsel, Frederic Jacotot, to the Management Board. Frederic joined the Board in April following the departure of the Company’s former CFO Reinhard Kandera.

Frederic Jacotot, a former Division Counsel at Abbott with over 25 years’ experience as a legal expert in the pharmaceutical industry, has been a Vice President and member of Valneva’s Executive Committee since 2013.
With these two additional appointments, Valneva´s Management Board now consists of Thomas Lingelbach, President & Chief Executive Officer (CEO), Franck Grimaud, President & Chief Business Officer (CBO), David Lawrence, Chief Financial Officer (CFO), Wolfgang Bender, Chief Medical Officer (CMO) and Frederic Jacotot, General Counsel and Corporate Secretary.

“We are pleased that we have been able to strengthen the Management Board with the addition of well recognized leaders in their field. We are convinced that we have an excellent, experienced and international Management team to support the Company´s further development into its next growth phase according to our strategic vision”, commented Frederic Grimaud, Chairman of the Supervisory Board and Thomas Lingelbach, CEO.
Valneva´s strategy is based on its vision to grow into a major and self-sustainable vaccine company by complementing organic growth with opportunistic M&A.

In order to become a sizable vaccine player, allowing Valneva to best leverage its current and future commercial and industrial infrastructures, the Company aims to grow its revenues to approximately €250 million in the mid-term.
By investing approximately 15 to 20% of Valneva’s revenues in Research & Development (R&D) annually, the Company is committed to discover, develop and deliver vaccine candidates in growing segments with strong medical need, and present innovative solutions to the benefit of individuals and society, creating upside for its shareholders.

About Valneva SE
Valneva is a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT®indicated for the prevention of Japanese encephalitis and DUKORAL®indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66®vaccine production cell line, IC31®adjuvant).

Valneva shares are tradable on Euronext-Paris, the Vienna stock exchange and Deutsche Börse’s electronic platform Xetra®. The Company has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at

Press contact
Valneva SE
Laetitia Bachelot-Fontaine
Head of Investor Relations & Corporate Communications
Tel: +02 28-07-14-19
Mobil: +33 (0)6 4516 7099
Email: investors(at)

Nina Waibel
Corporate Communications Specialist
Tel: +43 (0)1 206 20-1149
Email: communications(at)

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)